Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study

Trial Profile

Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs FF 10501 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 28 Apr 2017 Status changed from recruiting to completed.
    • 24 Dec 2015 According to a Strategia Therapeutics media release, a total of 5 dose cohorts (50-400 mg/m2 orally twice daily) have been enrolled. Additional Phase 1 dose cohorts of 500, 600 and 800 mg/m2 BID will be assessed. The Phase 2 portion of the study will open when a recommended Phase 2 dose is determined
    • 24 Dec 2015 Interim results published at the 57th American Society of Hematology Meeting, according to a Strategia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top